Update shared on 28 Oct 2025
Fair value Increased 0.91%Narrative Update on Vitrolife Analyst Price Target
Analysts have raised Vitrolife’s fair value estimate from SEK191.75 to SEK193.50. They highlight the company's improved profit margin outlook and stronger projected revenue growth as key drivers behind the revised target.
Valuation Changes
- The Fair Value Estimate has risen slightly from SEK191.75 to SEK193.50.
- The Discount Rate has increased marginally from 5.10% to 5.13%.
- The Revenue Growth Projection has improved from 5.83% to 6.80%.
- The Net Profit Margin forecast has increased from 18.62% to 19.56%.
- The Future P/E Ratio has declined from 38.45x to 36.32x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.